What's Happening?
The PRECEDE Foundation is working to raise awareness and optimism among Ashkenazi Jews who are predisposed to pancreatic cancer. The foundation, led by Jamie Brickell, a pancreatic cancer survivor, aims to increase the five-year survival rate of pancreatic cancer patients
to 50% through early detection. The PRECEDE study, involving over 60 academic medical centers worldwide, monitors individuals at elevated risk and develops early detection technologies. Despite the high risk among Ashkenazi Jews, the foundation faces challenges in engaging the community due to the perception of pancreatic cancer as a death sentence.
Why It's Important?
Pancreatic cancer is one of the deadliest forms of cancer, with a low survival rate. The Ashkenazi Jewish community is significantly predisposed to this disease, making early detection crucial. The PRECEDE Foundation's efforts to promote genetic testing and early screening could lead to earlier diagnoses and improved survival rates. Increasing awareness and participation in such programs is vital for reducing mortality rates and improving outcomes for high-risk groups. The foundation's work also highlights the need for more funding and research in cancer detection and prevention.
What's Next?
The PRECEDE Foundation plans to expand its study to include 20,000 participants globally, including in Israel. The foundation will continue to reach out to the Jewish community to promote genetic testing and early detection. Success in these efforts could lead to broader adoption of early detection technologies and potentially influence public health policies regarding cancer screening. The foundation's ongoing research and advocacy may also attract more funding and support from both public and private sectors.
